TY - JOUR
T1 - Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
AU - Wang, Hao
AU - Kaur, Gurbakhash
AU - Sankin, Alexander I.
AU - Chen, Fuxiang
AU - Guan, Fangxia
AU - Zang, Xingxing
N1 - Publisher Copyright:
© 2019 The Author(s).
PY - 2019/6/11
Y1 - 2019/6/11
N2 - Harnessing the power of the immune system to recognize and eliminate cancer cells is a longtime exploration. In the past decade, monoclonal antibody (mAb)-based immune checkpoint blockade (ICB) and chimeric antigen receptor T (CAR-T) cell therapy have proven to be safe and effective in hematologic malignancies. Despite the unprecedented success of ICB and CAR-T therapy, only a subset of patients can benefit partially due to immune dysfunction and lack of appropriate targets. Here, we review the preclinical and clinical advances of CTLA-4 and PD-L1/PD-1-based ICB and CD19-specific CAR-T cell therapy in hematologic malignancies. We also discuss the basic research and ongoing clinical trials on emerging immune checkpoints (Galectin-9/Tim-3, CD70/CD27, LAG-3, and LILRBs) and on new targets for CAR-T cell therapy (CD22, CD33, CD123, BCMA, CD38, and CD138) for the treatment of hematologic malignancies.
AB - Harnessing the power of the immune system to recognize and eliminate cancer cells is a longtime exploration. In the past decade, monoclonal antibody (mAb)-based immune checkpoint blockade (ICB) and chimeric antigen receptor T (CAR-T) cell therapy have proven to be safe and effective in hematologic malignancies. Despite the unprecedented success of ICB and CAR-T therapy, only a subset of patients can benefit partially due to immune dysfunction and lack of appropriate targets. Here, we review the preclinical and clinical advances of CTLA-4 and PD-L1/PD-1-based ICB and CD19-specific CAR-T cell therapy in hematologic malignancies. We also discuss the basic research and ongoing clinical trials on emerging immune checkpoints (Galectin-9/Tim-3, CD70/CD27, LAG-3, and LILRBs) and on new targets for CAR-T cell therapy (CD22, CD33, CD123, BCMA, CD38, and CD138) for the treatment of hematologic malignancies.
KW - CAR-T
KW - CTLA-4
KW - Hematologic malignancies
KW - Immune checkpoints
KW - Immunotherapy
KW - New targets
KW - PD-1
UR - http://www.scopus.com/inward/record.url?scp=85067196824&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067196824&partnerID=8YFLogxK
U2 - 10.1186/s13045-019-0746-1
DO - 10.1186/s13045-019-0746-1
M3 - Review article
C2 - 31186046
AN - SCOPUS:85067196824
SN - 1756-8722
VL - 12
JO - Journal of Hematology and Oncology
JF - Journal of Hematology and Oncology
IS - 1
M1 - 59
ER -
